Shalby Limited (NSE:SHALBY)
171.73
+2.12 (1.25%)
Jan 22, 2026, 3:30 PM IST
Shalby Revenue
Shalby had revenue of 2.85B INR in the quarter ending September 30, 2025, with 6.69% growth. This brings the company's revenue in the last twelve months to 11.22B, up 11.49% year-over-year. In the fiscal year ending March 31, 2025, Shalby had annual revenue of 10.87B with 16.41% growth.
Revenue (ttm)
11.22B
Revenue Growth
+11.49%
P/S Ratio
1.64
Revenue / Employee
4.33M
Employees
2,592
Market Cap
18.45B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 10.87B | 1.53B | 16.41% |
| Mar 31, 2024 | 9.34B | 1.29B | 16.00% |
| Mar 31, 2023 | 8.05B | 1.06B | 15.16% |
| Mar 31, 2022 | 6.99B | 2.68B | 62.21% |
| Mar 31, 2021 | 4.31B | -559.57M | -11.49% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 549.64B |
| Aurobindo Pharma | 325.14B |
| Cipla | 279.66B |
| Zydus Lifesciences | 244.94B |
| Apollo Hospitals Enterprise | 232.65B |
| Biocon | 164.76B |
| Alkem Laboratories | 138.90B |
| Mankind Pharma | 135.46B |
Shalby News
- 2 months ago - Shalby Ltd (BOM:540797) Q2 2026 Earnings Call Highlights: Navigating Growth Amidst Challenges - GuruFocus
- 2 months ago - Q2 2026 Shalby Ltd Earnings Call Transcript - GuruFocus
- 5 months ago - Shalby signs MoU with Bhartiya Skill Development University to launch B.Voc programs in healthcare - Business Upturn
- 5 months ago - Shalby shares drop over 2% as Q1 net profit falls 43% YoY to Rs 8.9 crore, Ebitda down 8% YoY - Business Upturn
- 1 year ago - Q3 2025 Shalby Ltd Earnings Call Transcript - GuruFocus
- 1 year ago - Shalby shares drop 4% as EBITDA falls 20.1% YoY in Q3 - Business Upturn
- 1 year ago - Shalby shares jump 3% after FDA approval for Duraniom knee replacement device - Business Upturn
- 1 year ago - Monogram Technologies announces strategic collaboration with Shalby Limited - Seeking Alpha